COA

KPV nothing more. nothing less.

KPV is a naturally occurring tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH). Studied in research involving melanocortin pathway activity, inflammatory modulation, and mucosal signaling.

Purity >99%Form Lyophilized PowderNo Endotoxins

Ships Tomorrow

Order within

10MG $45.00 Out of Stock
>99% Purity
cGMP-Compliant
SAME DAY SHIPPING
US MADE
Quantity Price Per Unit
5 – 9
10+

For research use only — not for human consumption, therapeutic, or diagnostic use. By adding to cart you acknowledge these terms.

Blank. Credentials

Institutional-grade credentials you can verify

Double Validation HPLC + MS
Priority Delivery Fast Shipping
Expert Support US-Based Team
Risk-Free 14-Day Guarantee
Volume Savings Tiered Pricing

About This Compound

Deep technical insights for clinical research

Primary Research Applications

This compound is supplied strictly for in-vitro and preclinical research use only. Primary applications include the areas below.

Inflammatory Bowel Disease Research

Reduces intestinal inflammation through PepT1-mediated transport and inhibition of NF-κB and MAP kinase signaling pathways.

Mucosal Barrier Protection

Accelerates mucosal healing and reduces pro-inflammatory cytokine production in colitis and inflammatory bowel models.

Research Community Feedback

"Consistency is paramount in our cellular model testing. Blank's peptides have maintained the tightest purity specs of any RUO vendor we've audited."

Dr. Julian Kessler

Lead Investigator, Biomatrix Labs

"The availability of detailed MS and HPLC data on the product page saved us two days of redundant internal verification. Professional grade synthesis."

Anika S. Singh

Synthetics Quality Control

"Finally, a supplier that doesn't hide behind consumer marketing. Stark, clear, and high-purity. Exactly what a modern lab needs."

Prof. David Emmerich

Applied Peptide Research

Complete The Protocol

Pairs & Supplies

The compounds and tools researchers stack with KPV.

KLOW

KLOW

$160.00
Add to Cart
BACTERIOSTATIC WATER

BACTERIOSTATIC WATER

$10.00
Add to Cart
DSIP

DSIP

$65.00
Add to Cart

Peer-Reviewed Literature

Related Studies

KPV · 2008

PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation

Gastroenterology

KPV inhibits NF-κB activation and pro-inflammatory cytokine secretion through PepT1 transporter mechanism. Oral administration reduced DSS- and TNBS-induced colitis incidence.

KPV · 2008

Melanocortin-Derived Tripeptide KPV Has Anti-Inflammatory Potential in Murine Models of Inflammatory Bowel Disease

Inflammatory Bowel Diseases

KPV demonstrated earlier recovery, stronger body weight regain, and significantly reduced inflammatory infiltrates in two IBD models, with effects partially independent of MC1R signaling.

KPV · 2017

Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis

Molecular Therapy

HA-KPV nanoparticles showed targeted delivery to colonic epithelial cells and macrophages, exerting combined effects against UC by accelerating mucosal healing and alleviating inflammation.

KPV · 2013

KPV Nanoparticles Effectively Treat Inflammatory Bowel Disease in Mice Through Oral Delivery

Journal of Controlled Release

KPV-loaded nanoparticles delivered orally showed significant anti-inflammatory efficacy in DSS-induced colitis models, reducing TNF-α and IL-6 while maintaining mucosal integrity, rivaling corticosteroid effects.

KPV · 2006

Anti-Inflammatory Effects of α-MSH Through p53-Mediated NF-κB Activation in Human Melanocytes

Journal of Biological Chemistry

KPV (C-terminal tripeptide of α-MSH) inhibited NF-κB translocation and downstream pro-inflammatory gene expression through a melanocortin receptor-independent mechanism, demonstrating direct intracellular anti-inflammatory action.

KPV · 2011

α-MSH Tripeptide Analogs Activate the Melanocortin MC1 Receptor and Reduce Mucosal Damage in Experimental Colitis

PLoS One

Systemic KPV administration reduced disease activity index, prevented colonic shortening, and preserved mucosal architecture in acute colitis models through MC1R-mediated and NF-κB-independent pathways.

From the Lab

Related Blog Posts